The 340B Drug Pricing Program, Hospital Prices, and Competition in Commercial Markets

Area of Science:

• Health economics
• Pharmaceutical policy
• Market analysis

Background:

• The 340B drug pricing program aims to reduce drug costs for eligible hospitals.
• Understanding how 340B eligibility impacts drug prices in commercial markets is crucial.
• Market competition may influence the pass-through of savings.

Purpose of the Study:

• To determine if 340B drug pricing program eligibility reduces prices for clinician-administered drugs in commercial insurance.
• To assess if these price reductions vary based on market competition.

Main Methods:

• A quasi-experimental study using a regression discontinuity design based on the 340B eligibility threshold (DSH percentage > 11.75%).
• Analysis of secondary claims data from the Health Care Cost Institute (HCCI) for non-profit and public acute care hospitals (2012-2014).
• Primary outcome: negotiated unit prices for high-spending outpatient drugs; secondary outcomes: drug volume and revenue.

Main Results:

• 340B eligibility was associated with a $605 median reduction in unit drug prices.
• Price reductions were significant in competitive markets (HHI ≤ 1800), with a $793 decrease (32% reduction).
• Effects were small and insignificant in highly concentrated markets; price reductions were offset by non-significant increases in drug volume.

Conclusions:

• Hospital 340B eligibility effectively reduced commercial drug prices, but only in competitive markets.
• Market competition plays a critical role in enabling policy-driven cost savings to be shared with payers and patients.
• These findings highlight the importance of market dynamics in the effectiveness of drug pricing policies.